JNJJanssen Pharmaceutical K.K.Running, no new patients
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Salivary Gland Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 31 (final count)
- Started
- Apr 7, 2020
- Main results expected
- Jun 9, 2021
- Fully finished
- Dec 31, 2027
- Results posted
- Jul 6, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: Up to 13 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04325828 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC